x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012849
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SOAT1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SOAT1 |
| UniProt No. | P35610 |
| Gene ID | 6646 |
| Gene Description | SOAT1 is an O-acyltransferase that functions in the endoplasmic reticulum to catalyze the formation of cholesterol esters from free cholesterol and long chain fatty acyl-coenzyme A. The cholesterol esters are incorporated into cytoplasmic lipid droplets, thereby preventing excess free cholesterol from inducing lipid-mediated cell toxicity, including ER stress. Research studies have shown that pharmacological inhibition of SOAT1 in tumor cells induced lipid-mediated cell toxicity that suppressed tumor cell growth and promoted tumor cell apoptosis. Pharmacological SOAT1 inhibition was also shown to stimulate autophagy-mediated proteolysis in microglia, leading to enhanced clearance of amyloid peptide Aβ42. Collectively, these findings suggest that SOAT1 inhibition may have therapeutic potential in both cancer and Alzheimer’s disease. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
